Ring Therapeutics develops medical gene therapeutics using an innovative viral vector platform designed to broaden the scope of DNA-based treatments beyond simple gene replacement. This platform targets disease sites with precision at the cellular and tissue level, addressing areas such as genetic disorders, ophthalmology, oncology, and metabolic disorders. This allows healthcare companies to deliver treatments tailored to specific diseases, utilizing a diverse range of modalities and mechanisms.

Investors Include:

The Invus Group, CJ Investment, Altitude Life Science Ventures, UPMC Enterprises, Flagship Pioneering, Alexandria Venture Investments, Kyowa Kirin, Partners Investment, T. Rowe Price Group.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund